-
公开(公告)号：US11531036B2
公开(公告)日：2022-12-20
申请号：US16608428
申请日：2018-04-26
发明人： Jesmond Dalli , Romain Alexandre Colas , Patricia Regina Soares De Souza , Mary Elizabeth Walker
IPC分类号： G01N33/92 , G01N33/543 , A01N1/02
摘要： A method, device, computer program and related immunoassay are disclosed for assessing the efficacy of a statin selected from, for example, selected from RvT1 (7,13,20-trihydroxy-8,10,14,16Z,18-docosapentaenoic acid), RvT2 (7,12,13-trihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), RvT3 (7,8,13-trihydroxy-9,11,14,16Z,19Z-docosapentaenoic acid) and RvT4 (7,13-dihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), for use in the treatment of an inflammatory condition in an individual patient, which comprises measuring the levels of at least one 13-series resolvin in biological samples obtained from the patient before and after administration of the statin, wherein an increase in the level of the resolvin after administration of the statin is indicative of efficacy of the statin. Also disclosed is a method of storing a biological sample to preserve lipid mediators in the sample comprising placing the sample in an organic solvent and storing the sample at a temperature of ≤−75° C.
-
公开(公告)号：US20220349886A1
公开(公告)日：2022-11-03
申请号：US17761046
申请日：2020-09-17
发明人： Jesmond Dalli , Romain Alexandre Colas , Costantino Pitzalis , Esteban Alberto Gomez Cifuentes , Conrad Bessant
IPC分类号： G01N33/564 , G01N33/92 , G16H50/30 , G16H20/10
摘要： The present invention provides a method for predicting whether a patient having, suspected of having, or at risk of developing an inflammatory condition will respond to treatment with a disease-modifying antirheumatic drug (DMARD) comprising measuring the level of at least one specialized pro-resolving mediator (SPM) in a DMARD naïve patient sample and classifying the patient as a predicted DMARD responder or a predicted DMARD non-responder. The present invention also provides a method of assessing the efficacy of a disease-modifying antirheumatic drug (DMARD) for use in the treatment of an inflammatory condition in a patient. The present invention also provides a method of predicting which rheumatoid arthritis pathotype a patient having, suspected of having, or at risk of developing rheumatoid arthritis will develop.
-
公开(公告)号：US20200215014A1
公开(公告)日：2020-07-09
申请号：US16648342
申请日：2018-09-19
IPC分类号： A61K31/202 , G01N33/569 , G01N33/92 , A61K9/00 , A61P9/00 , G16H10/40 , G16H20/10 , G16H50/30
摘要： A method of treating or preventing cardiovascular disease which comprises administering a therapeutically effective amount of at least one n-3 DPA-derived resolvin and/or upregulating or increasing the biosynthesis or activity of at least one n-3 DPA-derived resolvin. n-3 DPA-derived resolvins are normally regulated diurnally in the body and are linked to activation of platelets and leucocytes and formation of platelet-leukocyte aggregates. Dysfunctional regulation of n-3 DPA-derived resolvins may lead to systemic inflammation because of excessive inflammation-inducing eicosanoids, especially in the early hours of the morning. Further, decreased 5-LOX/15-LOX expression and increased systemic adenosine concentrations are found to be associated with reduced resolvin levels and increased risk of cardiovascular disease. n-3 DPA-derived resolvins are administered to achieve maximum absorption in the early hours. Also disclosed are n-3 DPA-derived resolvins for use in the treatment or prevention of cardiovascular disease, and methods for measuring the levels of n-3 DPA-derived resolvins and/or the expression or activity of adenosine or 5-LOX/15-LOX in biological samples obtained from a subject for assessing the subject's risk of cardiovascular disease.
-
-
搜索结果
3 条记录 (耗时 0.014 秒)
